Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Gilead Sciences    GILD

GILEAD SCIENCES (GILD)
My previous session
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsTweets
OFFRE

Gilead Sciences : offers its newest HIV drug candidate to patent pool for low-cost production

share with twitter share with LinkedIn share with facebook
share via e-mail
0
10/06/2017 | 12:13pm CEST

Gilead Sciences is licensing its newest HIV drug candidate, bictegravir, to the U.N.-backed Medicines Patent Pool, meaning it will be produced and sold at a lower cost in 116 low- and middle-income countries once it is approved.

Gilead said it will include the HIV-1 candidate in its existing agreements with generic drugmakers Sun Pharmaceutical Industries, Strides Shasun, Mylan and SeQuent Scientific, as a single agent or in fixed-dose combinations with other HIV medicines, upon regulatory approval in the U.S. It also will allow the MPP to sub-license it to other generic producers in India, China and South Africa.

Competition among manufacturers has reduced the lowest price of a Gilead HIV generic therapy by 80 percent since 2006, to as low as $3.50 per patient per month. Ninety-nine percent of people taking Gileads HIV therapies in developing countries receive generic medicine, Gilead said in an announcement today.

Of course, it is the branded version in the U.S. and Europe, where drug approvals are currently pending, that Gilead is most interested in and where it will compete with GlaxoSmithKlines $1.2 billion seller Tivicay (dolutegravir). The FDA has set a Feb.12, 2018 target date for consideration.

Analysts initially believed bictegravir, if approved, was going to be a red-hot competitor to the GSK med but phase 3 data released last spring cooled those expectations somewhat. While four studies of the investigational integrase strand transfer inhibitor hit their primary endpoints by measuring up to Tivicay and other antiretroviral agents, they didnt prove that bictegravir is superior. Then in data released today, it reported the same finding at 48 weeks.

GSK, which has been aggressively building its HIV focused ViiV Healthcare, is taking another tack in its assault on market leader Gileads $10 billion-plus HIV franchise. The U.K.-based company is betting on a two-drug, dolutegravir-containing regimen that could potentially cut down on the side-effect burden of Gileads three-drug approaches, and their cost, too.

(c) International 2006-2017, SANA Provided by SyndiGate Media Inc. (Syndigate.info)., source Middle East & North African Newspapers

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on GILEAD SCIENCES
09/20GILEAD SCIENCES' : Trademark Application for "WILKARTI" Filed
AQ
09/20GILEAD SCIENCES : Trademark Application for "CAARTUVY" Filed by Gilead Sciences
AQ
09/20GILEAD SCIENCES' : Trademark Application for "TUCAARTI" Filed
AQ
09/20GILEAD SCIENCES : Researchers Submit Patent Application, "Inhibitors Of Bruton'S..
AQ
09/20GILEAD SCIENCES : An Application for the Trademark "WILKARTA" Has Been Filed by ..
AQ
09/20GILEAD SCIENCES : An Application for the Trademark "SIZAXTA" Has Been Filed by G..
AQ
09/20GILEAD SCIENCES : An Application for the Trademark "YUZIKART" Has Been Filed by ..
AQ
09/20GILEAD SCIENCES' : Trademark Application for "OUIKARTA" Filed
AQ
09/20GILEAD SCIENCES : An Application for the Trademark "CYZAXTA" Has Been Filed by G..
AQ
09/20GILEAD SCIENCES : An Application for the Trademark "TUCARTY" Has Been Filed by G..
AQ
More news
News from SeekingAlpha
09/21Feds looking into free services from drug makers - WSJ 
09/21What's Next For Gilead? 
09/21Breaking Down The NASH Cirrhosis Market - Gilead Poised For Success, But Is I.. 
09/19My Quarterly Global Portfolio Update 
09/18AbbVie used kickbacks to boost Humira sales - CA insurance commissioner 
Financials ($)
Sales 2018 21 377 M
EBIT 2018 11 220 M
Net income 2018 6 650 M
Debt 2018 12 363 M
Yield 2018 3,01%
P/E ratio 2018 14,98
P/E ratio 2019 13,78
EV / Sales 2018 5,16x
EV / Sales 2019 5,12x
Capitalization 97 887 M
Chart GILEAD SCIENCES
Duration : Period :
Gilead Sciences Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GILEAD SCIENCES
Short TermMid-TermLong Term
TrendsNeutralBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 27
Average target price 88,0 $
Spread / Average Target 17%
EPS Revisions
Managers
NameTitle
John F. Milligan President, Chief Executive Officer & Director
John C. Martin Chairman
Robin L. Washington CFO, Principal Accounting Officer & Executive VP
John G. McHutchison Chief Scientific Officer
George Pratt Shultz Director-Emeritus
Sector and Competitors
1st jan.Capitalization (M$)
GILEAD SCIENCES5.40%97 887
VERTEX PHARMACEUTICALS20.46%46 021
REGENERON PHARMACEUTICALS3.00%41 426
NEUROCRINE BIOSCIENCES, INC.54.17%10 822
GENMAB2.04%10 170
SAREPTA THERAPEUTICS INC165.26%9 806